Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BMS, Prosetta alliance to focus on antivirals
September 2012
SHARING OPTIONS:

SAN FRANCISCO—Bristol-Myers Squibb Co. (BMS) has inked a multi-year collaboration with Prosetta Antiviral under which the companies will discover and develop drug candidates that represent novel classes of antiviral drugs, specifically compounds proven to block viral capsid assembly. The collaboration will use Prosetta's proprietary drug discovery platform, and per the agreement, BMS has the right to develop and commercialize products that result. Prosetta will receive an upfront payment as well as multiyear research funding, and is eligible to receive milestone payments and royalties based on worldwide sales of drugs produced by the agreement.
 
"We greatly value this opportunity to collaborate with Bristol-Myers Squibb scientists in a joint program dedicated to a completely new approach to protecting human health against viral infections," said Vishwanath Lingappa, chief technology officer and co-CEO of Prosetta, in a statement.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.